All News

CV,risk,MI,heart,cardiac

A Modifiable Vascular Risk in SLE

MedPage Today

Atherosclerosis progression was more than twice as common in younger people with SLE than in healthy controls in a prospective study from Greece, but the rate difference narrowed substantially with sustained SLE remission and conventional cardiovascular risk factor management.

Read Article
lupus,nephritis,GN

Best of 2024: Upside/Downside of Steroids in Lupus Nephritis

Jack Cush, MD

A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis demonstrates both the benefits and harms to early glucocorticoid regimens on lupus outcomes.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus

Jack Cush, MD

Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).

Read Article
RheumNow Podcast square

Bah Humbug Vitamin D (12.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
price%20dollar%20pill.jpg

Abuse of the Safety-Net 340B Drug Programs

Jack Cush, MD

Dr. Madelaine Feldman has written an important commentary on the 340B Drug Pricing Program, a safety-net program that would allow vulnerable populations to receive expensive new therapies. But she points out that "this well-intentioned program has strayed from its original purpose", allowing certain hospitals and for-profit pharmacies to exploit the program.

Read Article
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/ug2ZzzSrGi https://t.co/O6r1e8ioO0

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus https://t.co/aNk5pgBpiJ https://t.co/C427ayULng

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 5063 SLE patients, found fibromyalgia (FM) 15.8% (high heterogeneity I2- 98%). SLE pts had a 3.7 fold higher risk of FM. FM in SLE was a confounder in assessing disease activity and treatment response. FM is a frequent comorbidity in SLE https://t.co/0fSIl480PG https://t.co/6ZtAovPVnD

Links:

Dr. John Cush RheumNow ( View Tweet)
A re-evaluation of lupus arthritis. Old dogma is RA is erosive and SLE non-erosive. With better imaging, lupus arthritis can be erosive. Vivianne Malstrom. @RheumNow #ACR24 https://t.co/dFRnmGMGls https://t.co/LNoCtmtVuI

Links:

Dr. John Cush RheumNow ( View Tweet)
Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/dr3M3cnjRG https://t.co/1wewEuJRAl

Links:

Dr. John Cush RheumNow ( View Tweet)
A cohort of 9 patients with Anti-MDA5 DM with RPILD who was treated with combination of RTX, JAKi, and GCS had significantly bettery survival compared to historical cohort in this abstract! #ACR24 @RheumNow https://t.co/PMVn5Pb1b3

Links:

Dr. John Cush RheumNow ( View Tweet)

Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus https://t.co/zLxEOnWjpB https://t.co/I8jBcxO6rH

Links:

Dr. John Cush RheumNow ( View Tweet)
12 minute JAMA Podcast on Dx & Rx of Lupus - featuring Caroline H. Siegel, MD, from HSS in NYC. https://t.co/4iHdQTFxxw https://t.co/zrNsartPlq

Links:

Dr. John Cush RheumNow ( View Tweet)
ANA neg, but ENA pos should we care about that result? PPV 5.5% here (similar to 6% prev @EricFMorand: https://t.co/7Lo0DgHtXT) and how many really needed the serology? Anxiety? Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️ #ACR24 ABST1930 @RheumNow… https://t.co/lZ1TJxTqhs https://t.co/itx0TCFFjl

Links:

Dr. John Cush RheumNow ( View Tweet)
Great table re:side effects of even low dose steroids in RA Likely generalizes to other diseases ie PMR, SLE P in prednisone stands for poison! #ACR24 @RheumNow https://t.co/2bFy6dwl96 https://t.co/YDtjSX054I

Links:

Dr. John Cush RheumNow ( View Tweet)
If high +ANA and NO #rheumatic #disease LOOK 👀 at #LIVER #Autoimmune #hepatitis And #alcoholic #liver #dx #ACRBest #ACR24 @rheumnow abst#0627 https://t.co/0bwfgNnB0e

Links:

Dr. John Cush RheumNow ( View Tweet)

A Fibroblast Renaissance Dr. Andrea Fava at the 2024 ACR Convergence meeting in Washington, DC. https://t.co/GQXWkqMkIW https://t.co/W6UXT4HCeg

Links:

Dr. John Cush RheumNow ( View Tweet)
41 "Rhupus" pts were compared to 160 SLE and 709 RA pts. Rhupus pts have a younger onset age than RA (P=0.032), but older than SLE (P=0.008). ~20% initially presented w/ SLE Sxs. Rhupus commonly has ILD, hyperglobulinemia & Lab abnormalities (61%), but seldom renal or CNS dz… https://t.co/m7VL6HHdUN https://t.co/i3knGVQYvj
Dr. John Cush RheumNow ( View Tweet)
41 "Rhupus" pts were compared to 160 SLE and 709 RA pts. Rhupus pts have a younger onset age than RA (P=0.032), but older than SLE (P=0.008). ~20% initially presented w/ SLE Sxs. Rhupus commonly has ILD, hyperglobulinemia & Lab abnormalities (61%), but seldom renal or CNS dz… https://t.co/pqfmFGT0D6 https://t.co/zo0APuAcQS
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Beyond the Needle: Redefining the Assessment of Lupus Nephritis Lupus nephritis is one of the most silent and severe manifestations of systemic lupus erythematosus (SLE). When not captured early, patients are at high risk of progressing to end-stage renal disease, which… https://t.co/ctngE0bMkX https://t.co/koDBZaPc19
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×